373 related articles for article (PubMed ID: 33023630)
1. Functional benefits of corticosteroid and IVIG combination therapy in a coronary artery endothelial cell model of Kawasaki disease.
Inoue T; Murakami S; Matsumoto K; Matsuda A
Pediatr Rheumatol Online J; 2020 Oct; 18(1):76. PubMed ID: 33023630
[TBL] [Abstract][Full Text] [Related]
2. Monocyte-Derived Interleukin-1β As the Driver of S100A12-Induced Sterile Inflammatory Activation of Human Coronary Artery Endothelial Cells: Implications for the Pathogenesis of Kawasaki Disease.
Armaroli G; Verweyen E; Pretzer C; Kessel K; Hirono K; Ichida F; Okabe M; Cabral DA; Foell D; Brown KL; Kessel C
Arthritis Rheumatol; 2019 May; 71(5):792-804. PubMed ID: 30447136
[TBL] [Abstract][Full Text] [Related]
3. Anti-inflammatory effects of high-dose IgG on TNF-α-activated human coronary artery endothelial cells.
Matsuda A; Morita H; Unno H; Saito H; Matsumoto K; Hirao Y; Munechika K; Abe J
Eur J Immunol; 2012 Aug; 42(8):2121-31. PubMed ID: 22585560
[TBL] [Abstract][Full Text] [Related]
4. Anti-inflammatory effect of intravenous immunoglobulin in comparison with dexamethasone in vitro: implication for treatment of Kawasaki disease.
Makata H; Ichiyama T; Uchi R; Takekawa T; Matsubara T; Furukawa S
Naunyn Schmiedebergs Arch Pharmacol; 2006 Aug; 373(5):325-32. PubMed ID: 16896803
[TBL] [Abstract][Full Text] [Related]
5. Prednisolone Suppresses the Extracellular Release of HMGB-1 and Associated Inflammatory Pathways in Kawasaki Disease.
Ueno K; Nomura Y; Morita Y; Kawano Y
Front Immunol; 2021; 12():640315. PubMed ID: 34079539
[TBL] [Abstract][Full Text] [Related]
6. [Recombinant human interleukin 35 (rhIL-35) alleviates the damage of coronary artery endothelial cells in Kawasaki disease by inhibiting NF-κB pathway].
Tian Z; Zhou Z; Yang Y; Li J; Hu L; Jiao R
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2022 Oct; 38(10):880-885. PubMed ID: 36163618
[TBL] [Abstract][Full Text] [Related]
7. Anti-inflammatory effect of resveratrol in human coronary arterial endothelial cells via induction of autophagy: implication for the treatment of Kawasaki disease.
Huang FC; Kuo HC; Huang YH; Yu HR; Li SC; Kuo HC
BMC Pharmacol Toxicol; 2017 Jan; 18(1):3. PubMed ID: 28069066
[TBL] [Abstract][Full Text] [Related]
8. [Biomarkers associated with unresponsiveness to IVIG in children with Kawasaki disease].
Abe J; Matsuda A
Nihon Rinsho Meneki Gakkai Kaishi; 2013; 36(1):27-34. PubMed ID: 23445729
[TBL] [Abstract][Full Text] [Related]
9. The effects of glucocorticoid plus intravenous immunoglobulin (IVIG) vs IVIG alone on platelet activation in children with Kawasaki disease.
Wang QQ; Zheng LY; Zhao S
Turk J Pediatr; 2023; 65(4):640-649. PubMed ID: 37661679
[TBL] [Abstract][Full Text] [Related]
10. HMGB1 gene polymorphism is associated with coronary artery lesions and intravenous immunoglobulin resistance in Kawasaki disease.
Ahn JG; Bae Y; Shin D; Nam J; Kim KY; Kim DS
Rheumatology (Oxford); 2019 May; 58(5):770-775. PubMed ID: 30535242
[TBL] [Abstract][Full Text] [Related]
11. Clinical outcomes of initial dexamethasone treatment combined with a single high dose of intravenous immunoglobulin for primary treatment of Kawasaki disease.
Lim YJ; Jung JW
Yonsei Med J; 2014 Sep; 55(5):1260-6. PubMed ID: 25048483
[TBL] [Abstract][Full Text] [Related]
12. 1α,25-Dihydroxyvitamin D(3) inhibits vascular cellular adhesion molecule-1 expression and interleukin-8 production in human coronary arterial endothelial cells.
Kudo K; Hasegawa S; Suzuki Y; Hirano R; Wakiguchi H; Kittaka S; Ichiyama T
J Steroid Biochem Mol Biol; 2012 Nov; 132(3-5):290-4. PubMed ID: 22841897
[TBL] [Abstract][Full Text] [Related]
13. Interleukin-6 is prone to be a candidate biomarker for predicting incomplete and IVIG nonresponsive Kawasaki disease rather than coronary artery aneurysm.
Wu Y; Liu FF; Xu Y; Wang JJ; Samadli S; Wu YF; Liu HH; Chen WX; Luo HH; Zhang DD; Wei W; Hu P
Clin Exp Med; 2019 May; 19(2):173-181. PubMed ID: 30617865
[TBL] [Abstract][Full Text] [Related]
14. Intravenous immunoglobulin plus corticosteroid to prevent coronary artery abnormalities in Kawasaki disease: a meta-analysis.
Chen S; Dong Y; Yin Y; Krucoff MW
Heart; 2013 Jan; 99(2):76-82. PubMed ID: 22869678
[TBL] [Abstract][Full Text] [Related]
15. IL-1 Signaling Is Critically Required in Stromal Cells in Kawasaki Disease Vasculitis Mouse Model: Role of Both IL-1α and IL-1β.
Lee Y; Wakita D; Dagvadorj J; Shimada K; Chen S; Huang G; Lehman TJ; Fishbein MC; Hoffman HM; Crother TR; Arditi M
Arterioscler Thromb Vasc Biol; 2015 Dec; 35(12):2605-16. PubMed ID: 26515418
[TBL] [Abstract][Full Text] [Related]
16. Delayed intravenous immunoglobulin treatment increased the risk of coronary artery lesions in children with Kawasaki disease at different status.
Qiu H; He Y; Rong X; Ren Y; Pan L; Chu M; Wu R; Shi H
Postgrad Med; 2018 May; 130(4):442-447. PubMed ID: 29745742
[TBL] [Abstract][Full Text] [Related]
17. Berberine protects Kawasaki disease-induced human coronary artery endothelial cells dysfunction by inhibiting of oxidative and endoplasmic reticulum stress.
Xu M; Qi Q; Men L; Wang S; Li M; Xiao M; Chen X; Wang S; Wang G; Jia H; Liu C
Vascul Pharmacol; 2020 Apr; 127():106660. PubMed ID: 32070767
[TBL] [Abstract][Full Text] [Related]
18. Aberrantly decreased levels of NKG2D expression in children with kawasaki disease.
Ge X; Li CR; Yang J; Wang GB
Scand J Immunol; 2013 May; 77(5):389-97. PubMed ID: 23298273
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of intravenous immunoglobulin plus prednisolone therapy in patients with Kawasaki disease (Post RAISE): a multicentre, prospective cohort study.
Miyata K; Kaneko T; Morikawa Y; Sakakibara H; Matsushima T; Misawa M; Takahashi T; Nakazawa M; Tamame T; Tsuchihashi T; Yamashita Y; Obonai T; Chiga M; Hori N; Komiyama O; Yamagishi H; Miura M;
Lancet Child Adolesc Health; 2018 Dec; 2(12):855-862. PubMed ID: 30337183
[TBL] [Abstract][Full Text] [Related]
20. Rationale and study design for a phase I/IIa trial of anakinra in children with Kawasaki disease and early coronary artery abnormalities (the ANAKID trial).
Tremoulet AH; Jain S; Kim S; Newburger J; Arditi M; Franco A; Best B; Burns JC
Contemp Clin Trials; 2016 May; 48():70-5. PubMed ID: 27080929
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
